Chemomab Therapeutics: A High-Risk, High-Reward Binary Bet on Transformative PSC Drug and Critical Near-Term Funding
Overview
Chemomab Therapeutics is a clinical-stage biotech pursuing transformative therapies for fibro-inflammatory conditions, with all operational focus and valuation tied to its sole asset, nebokitug. The company has achieved key de-risking milestones: successful Phase 2 data and FDA alignment for a streamlined, pivotal Phase 3 trial in PSC, a disease with no approved disease-modifying treatments and a large commercial market potential. Despite strong scientific and regulatory progress, Chemomab faces a critical funding shortfall, with the primary near-term catalyst being a needed pharmaceutical partnership to advance nebokitug to market. The market cap reflects this acute financial risk, discounting significant potential for value realization should funding be secured.